Lantheus Holdings Inc. has announced an exclusive licensing agreement with GE HealthCare for the development, manufacturing, and commercialization of Lantheus' prostate cancer imaging agent, piflufolastat F18, known as PYLARIFY® in the U.S. market, in Japan. This collaboration aims to expand the availability of targeted PET imaging agents for prostate cancer diagnostics and companion diagnostic use in Japan. As part of the agreement, GE HealthCare will pay Lantheus an upfront license fee, development milestones, and tiered royalties based on product sales in Japan. A Joint Steering Committee will be established to oversee development and commercialization activities. The initiative addresses a critical clinical need in Japan, a country with the third highest number of prostate cancer cases globally, and is expected to enhance the detection and care of prostate cancer in the region.